Did We Just Cure High LDL for Life?

Participants are excited by early human trial data showing large LDL drops from a single base-editing infusion, yet they note current gene therapies remain extremely expensive and unproven for long-term safety in non-fatal conditions. Some already use existing PCSK9 inhibitors and statins while hoping for future access; others question whether nature's higher cholesterol levels might serve unknown purposes and worry about downstream effects like dementia risk or postponed rather than prevented events. Personal stories range from lifelong low readings possibly tied to lifestyle to family histories of early heart attacks despite fitness.

• One infusion reportedly cut LDL up to 62 percent in the first human test of this editing approach
• Approved gene therapies today cost millions and carry cancer risks that may outweigh benefits for lipid disorders
• Animal research routinely knocks out genes in targeted ways, but human translation stays slow and costly
• Some users see no biological upside to high cholesterol and cite untreated familial cases with early cardiac deaths
• HDL levels show diminishing returns above roughly 75 and possible dementia links when abnormally elevated
• Multiple factors beyond cholesterol, including inflammation and calcium balance, influence plaque formation

Whether high cholesterol ever confers any advantage and whether statin-style lowering merely delays rather than prevents heart attacks

Long-term safety, cancer risk, and unforeseen consequences of permanent gene edits in otherwise healthy people

Nothing here is advice.